These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16079829)

  • 21. [Topics on gene abnormality in endometrial cancer].
    Shiozawa T; Konishi I
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():259-63. PubMed ID: 15535247
    [No Abstract]   [Full Text] [Related]  

  • 22. The TRIP from ULF to ARF.
    Collado M; Serrano M
    Cancer Cell; 2010 Apr; 17(4):317-8. PubMed ID: 20385357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment and characterization of nine human brain tumor cell lines.
    Shin KH; Choe G; Park YJ; Jang JH; Jung HW; Park JG
    In Vitro Cell Dev Biol Anim; 2001; 37(10):625-8. PubMed ID: 11776963
    [No Abstract]   [Full Text] [Related]  

  • 24. Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine.
    McGregor F; Muntoni A; Fleming J; Brown J; Felix DH; MacDonald DG; Parkinson EK; Harrison PR
    Cancer Res; 2002 Aug; 62(16):4757-66. PubMed ID: 12183435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dysregulated PTEN-PKB and negative receptor status in human breast cancer.
    Shi W; Zhang X; Pintilie M; Ma N; Miller N; Banerjee D; Tsao MS; Mak T; Fyles A; Liu FF
    Int J Cancer; 2003 Mar; 104(2):195-203. PubMed ID: 12569575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The coordinate regulation of the p53 and mTOR pathways in cells.
    Feng Z; Zhang H; Levine AJ; Jin S
    Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8204-9. PubMed ID: 15928081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stem cells. PTEN--coupling tumor suppression to stem cells?
    Penninger JM; Woodgett J
    Science; 2001 Dec; 294(5549):2116-8. PubMed ID: 11739945
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
    Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
    Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of the candidate tumor suppressor BTG3 triggers acute cellular senescence via the ERK-JMJD3-p16(INK4a) signaling axis.
    Lin TY; Cheng YC; Yang HC; Lin WC; Wang CC; Lai PL; Shieh SY
    Oncogene; 2012 Jul; 31(27):3287-97. PubMed ID: 22020331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.
    Zhou M; Gu L; Findley HW; Jiang R; Woods WG
    Cancer Res; 2003 Oct; 63(19):6357-62. PubMed ID: 14559824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional roles of Akt signaling in mouse skin tumorigenesis.
    Segrelles C; Ruiz S; Perez P; Murga C; Santos M; Budunova IV; Martínez J; Larcher F; Slaga TJ; Gutkind JS; Jorcano JL; Paramio JM
    Oncogene; 2002 Jan; 21(1):53-64. PubMed ID: 11791176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [PTEN--a new tumor inhibitory gene].
    Tian X; Wu H
    Zhonghua Bing Li Xue Za Zhi; 2000 Dec; 29(6):455-7. PubMed ID: 12790140
    [No Abstract]   [Full Text] [Related]  

  • 33. p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes.
    Fung C; Pupo GM; Scolyer RA; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2013 Mar; 26(2):236-46. PubMed ID: 23279822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression.
    Ma L; Teruya-Feldstein J; Behrendt N; Chen Z; Noda T; Hino O; Cordon-Cardo C; Pandolfi PP
    Genes Dev; 2005 Aug; 19(15):1779-86. PubMed ID: 16027168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival.
    Yang G; Ayala G; De Marzo A; Tian W; Frolov A; Wheeler TM; Thompson TC; Harper JW
    Clin Cancer Res; 2002 Nov; 8(11):3419-26. PubMed ID: 12429629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation.
    Reiss K; Wang JY; Romano G; Furnari FB; Cavenee WK; Morrione A; Tu X; Baserga R
    Oncogene; 2000 May; 19(22):2687-94. PubMed ID: 10851068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors.
    Haferkamp S; Scurr LL; Becker TM; Frausto M; Kefford RF; Rizos H
    J Invest Dermatol; 2009 Aug; 129(8):1983-91. PubMed ID: 19212341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scientists hopeful as they uncover molecular clues to prostate cancer.
    Vanchieri C
    J Natl Cancer Inst; 2005 Feb; 97(3):168-9. PubMed ID: 15687357
    [No Abstract]   [Full Text] [Related]  

  • 39. Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis.
    Ferguson B; Konrad Muller H; Handoko HY; Khosrotehrani K; Beermann F; Hacker E; Soyer HP; Bosenberg M; Walker GJ
    Pigment Cell Melanoma Res; 2010 Dec; 23(6):771-80. PubMed ID: 20718941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway.
    Yuan XJ; Whang YE
    Oncogene; 2002 Jan; 21(2):319-27. PubMed ID: 11803475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.